• UCLA Health
  • myUCLAhealth
  • School of Medicine
UCLA Obstetrics and Gynecology

UCLA Obstetrics and Gynecology

UCLA Obstetrics and Gynecology
  • About Us
    • Chair's Welcome
    • Contact Us
    • Giving
    • Job Listings
    • News
    • Webinars
  • Clinical Programs
    • Chronic Pelvic Pain Program
    • Family Planning
    • Fertility and Reproductive Health Center
    • Fibroid Treatment Program
    • Gynecologic Oncology
    • Gynecology
    • Labor and Delivery
    • Maternal Fetal Medicine
    • Nurse Midwives
    • Minimally Invasive & Robotic Surgery
    • Obstetrics
    • Women's Pelvic Health
  • Conditions Treated
    • Cervical Cancer
    • Cervical Insufficiency
    • Congenital Abnormalities
    • Endometriosis
    • Fibroids
    • Hirsutism
    • Infertility
    • Menopause
    • Ovarian Fallopian Tube and Primary Peritoneal Cancer
    • Polycystic Ovary Syndrome (PCOS)
    • Pregnancy
    • Premenstrual Syndrome (PMS)
    • Recurrent Pregnancy Loss
    • Reproductive Surgery
    • Sexually-transmitted Diseases
    • Urinary Tract Infection
    • Uterine / Endometrial Cancer
    • Vaginal Yeast Infection
    • Vulvar and Vaginal Cancer
    • Vulvodynia
  • For Patients
    • Coronavirus
    • Patient Stories
    • myUCLAhealth
    • Appointments
    • Clinical Updates
    • FAQs
    • Find a Doctor
    • First Visit
    • Health Plans
    • Locations
    • Medical Records
    • Patient Videos
    • Physicians Update
    • Pregnancy
    • Prescription Refill
    • Resources
    • Vital Signs Newsletters
    • Webinars
  • Clinical Trials
  • Research
    • Yalda Afshar MD PhD Lab
    • Sandra Orsulic PhD Lab
    • Women's Reproductive Health Research Program
  • Education
    • Residency
    • Fellowship Programs
    • Housestaff Roster 2020-21
    • Calendar of Events
    • Grand Rounds and Conferences
    • Medical Students
    • Aerial Tour: Why Choose UCLA?
    • Contact Academic Office
  • Our Expert Team
    • Appointment Request
    • Chronic Pelvic Pain
    • Family Planning
    • Fertility & Reproductive Health
    • Fibroid Treatment
    • Gynecologic Oncology
    • Gynecology
    • Minimally Invasive & Robotic Surgery
    • Nurse Midwives
    • Obstetrics
    • Maternal Fetal Medicine
    • Women's Pelvic Health
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

UCLA Obstetrics and Gynecology

Clinical Trials

  1. Home
  2. Clinical Trials
  3. Treatment of Recurrent Cervical Cancer

Treatment of Recurrent Cervical Cancer

Share this

GOG 3028: Testing  AGEN2034 (ant-PD1) alone or in combination with AGEN 1884 (CTLA-4)

Clinical Trial for Recurrent Cervical Cancer

Women with cervical cancer who relapsed or progressed after receiving first-line platinum-based chemotherapymay be eligible to participate in this trial. The treatment, which will consist of two treatment arms, will assess the efficacy and safety of AGEN2034 administered with placebo or with AGEN1884. AGEN2034 and AGEN1884 are antibodies that activate the immune system to destroy cancer cells by blocking two negative regulators of immune activation, PD-1 (programmed cell death protein 1)and CTLA-4 (cytotoxic T-lymphocyte antigen-4), respectively.  

Participants must meet the following criteria be eligible for the trial:

  1. Have metastatic, locally advanced, and/or unresectable cervical cancer that relapsed after a platinum-based treatment
  2. Willing to provide Informed Consent
  3. Age 18+

If you've answered yes to all of the above questions, please
Email:obgynresearch@mednet.ucla.edu or Call: (310) 794-9652.

Once in the study, participants will be randomized (like drawing numbers from a hat) to one of two treatment arms.Patients in Treatment Arm 1 will receive monotherapy of AGEN2034 with placebo. Patients in Treatment Arm 2 will receive AGEN2034 with AGEN1884 as combination therapy.Physicians, patients, and research personnel will not know whether patient has received AGEN2034 + placebo (Treatment Arm 1) or AGEN2034 + AGEN1884 (Treatment Arm 2).Treatment will last a maximum of 24 months or until confirmed progression, unacceptable toxicity, or any criterion for stopping the study or withdrawal from the trial occurs.

All participants enrolled in the study will undergo the following testing:

  • Physical Exam
  • Blood Sample Collection
  • Urine Sample Collection
  • Quality of Life questionnaires
  • ECG
  • Tumor biopsy
  • Tumor Imaging by CT Scan
  • Brain Imaging by MRI (only necessary if clinically indicated)

UCLA Protocol ID: IRB# 19-000800

Please call (310) 794-9652 to learn more. In order to protect your privacy, please do not include any personal health information if you choose to e-mail us.
Learn more at UCLAHealth Clinical Trials >

 

Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest